Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCL@Bmi1 siRNA
- Development stage
- Preclinical
- Lead developer
- Affiliated Hospital of Qinghai University
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CCL@Bmi1 siRNA** is an investigational lipid-coated calcium carbonate nanocapsule formulation that co-delivers cisplatin and a small interfering RNA directed against **BMI1**. The siRNA component suppresses BMI1-associated cancer stem-cell programs and multidrug-resistance biology, while cisplatin produces DNA damage. In cisplatin-resistant ovarian cancer cell and mouse models, the formulation increased cisplatin sensitivity and suppressed tumor growth without notable systemic toxicity. It is a preclinical nanotherapeutic reported by investigators at Qinghai University Affiliated Hospital and Qinghai University. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41922680/))
- Other names
- CCL@Bmi1 siRNA
02
Targets
BMI1 (Polycomb complex protein BMI-1)
Beyond the preview
Go deeper on CCL@Bmi1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCL@Bmi1 siRNA.